Adagrasib(Krazati)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Krazati(Adagrasib) Instructions:Uses,Dosage, Side Effects
Adagrasib, branded as KRAZATI, is an oral medication that targets KRAS G12C mutations, offering a targeted therapy option for patients with KRAS G12C-mutated non-small cell lung cancer and colorectal cancer. The drug works by irreversibly inhibiting the mutated KRAS protein, blocking its abnormal signaling pathway, and inhibiting tumor growth.
It is used both as a single agent for NSCLC and in combination with cetuximab for the treatment of CRC. It has shown promising results in clinical trials, providing a treatment option for patients with limited alternatives due to previous systemic therapies.
Generic name
Adagrasib(Krazati)
Alternative Names
Krazati
Indications
KRAZATI (adagrasib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that harbor the KRAS G12C mutation. This includes patients who have received at least one prior systemic therapy.
Therapeutic Target
KRAS G12C
Active Ingredients
Adagrasib
specifications
200mg*180 capsules
Description
KRAZATI (adagrasib) is a selective, small-molecule inhibitor of the KRAS G12C mutation. The drug specifically targets and irreversibly inhibits the mutated KRAS protein, which is a key driver in the pathogenesis of certain cancers, particularly NSCLC. By binding to the cysteine residue at the G12C mutation site, KRAZATI prevents the activation of downstream signaling pathways responsible for cell growth and survival, thus inhibiting tumor progression. This targeted approach distinguishes KRAZATI from traditional chemotherapies.
Dosage and Administration
The recommended dose of KRAZATI is 600 mg orally once daily.
RELATED ARTICLES
Side Effects of Adagrasib
Adagrasib is an irreversible inhibitor of KRASG12C mutation, indicated for the treatment of locally advanced or...
Wednesday, December 3rd, 2025, 09:19
Dosage and Administration of Adagrasib
Adagrasib is an irreversible inhibitor of KRASG12C mutation, mainly used for the treatment of non-small cell lung...
Wednesday, December 3rd, 2025, 09:14
What Are the Indications of Adagrasib?
Adagrasib is an innovative KRASG12C inhibitor, which was first approved for marketing in the United States in 2022....
Tuesday, December 2nd, 2025, 11:20
Precautions for use of Adagrasib
Adagrasib is an important therapeutic drug, and its correct use and precautions are crucial to ensure the...
Wednesday, July 2nd, 2025, 16:06
Contact Us
Mailbox:Info@Lucius.La
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved
